IPO
IPO filing, visualized

WINDWARD BIO GROUP AG

Long-acting antibody medicines for asthma, COPD and eczema · Basel, Switzerland

WWB · NasdaqSwitzerlandF-1/A · Nov 9, 2026Priced Nov 12, 2026

Priced Nov 12, 2026 · range was $16–$18 · latest SEC filing Nov 16, 2026.

Pinch-zoom for details.

The offering

Price range
$16–$18
per share
Shares offered
10.3M
sold by the company
Raise at $17 midpoint
$175M
10,294,117 × $17, before fees
Net proceeds (company est.)
$156M
at $17 a share

What the company does

Windward Bio is a clinical-stage biotech developing ultra-long-acting antibody medicines for asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis.

Its candidates, WIN378 and WIN027, are designed to stay in the body longer than current treatments so patients need fewer doses. It has no approved products.

Operating result

Fiscal year

1st half

Net result

Fiscal year

1st half

Things to weigh

  • Loss-making: net loss of $42.6M in H1 2026.
  • No approved products; the summary statement of operations shows no revenue.
  • The company was formed in July 2024, so there is little operating history.

The numbers

$Jul 5–Dec 31, 2024FY2025YoYH1 2025H1 2026Change
Operating result(1.19M)(51.8M)n/m(23.3M)(44.7M)−91.9%
Net result(1.19M)(48.3M)n/m(22.8M)(42.6M)−87.4%
$Jul 5–Dec 31, 2024FY2025YoY
Operating result(1.19M)(51.8M)n/m
Net result(1.19M)(48.3M)n/m
$H1 2025H1 2026Change
Operating result(23.3M)(44.7M)−91.9%
Net result(22.8M)(42.6M)−87.4%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. Early-stage drug developer with little operating history to judge it by.
  2. Has lost money since it started and expects more losses.
  3. Will need more funding after this IPO to keep its trials going.
  4. No approved products: success depends on clinical trial results.

In plain English, from the filing's risk factors.

Strategy

The filing doesn't set out its strategy in a list we could read.

Source: WINDWARD BIO GROUP AG's Form F-1/A, filed with the SEC on Nov 9, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.